Navigating New Treatment Paradigms in Relapse or Refractory Multiple Myeloma 

Originally presented at HOPA's 13th Annual Conference, March 2017.

In 2015 the U.S. Food and Drug Administration (FDA) approved four new agents for the treatment of relapsed or refractory MM. In February, the FDA approved panobinostat (Farydak), the first histone deacetylase (HDAC) inhibitor to receive FDA approval. In November, the FDA accelerated the approval of daratumumab (Darzalex), the first-ever monoclonal antibody and immunotherapy for MM. In December, the second monoclonal antibody and immunotherapy option, elotuzumab (Empliciti), received FDA approval. Finally, ixazomib (Ninlaro), the fourth drug for MM and first oral proteasome inhibitor, was approved. In this session we will discuss the mechanism of action and adverse-event profile for each of these new agents.

Learning Objectives

  • Describe the new treatment options for multiple myeloma (MM) patients who have relapsed or are refractory to multiple lines of therapy.
  • Discuss the mechanism of action and adverse-event profile of the new agents.


Houry Leblebjian, PharmD BCOP

Houry Leblebjian, a board certified oncology pharmacist, received her PharmD degree from the Lebanese American University. She completed her pharmacy practice residency at UMass Memorial Medical Center and an oncology pharmacy practice residency at the Dana Farber/Brigham and Women’s Cancer Center, Boston, MA. She works as a clinical pharmacy specialist in oncology/hematology at Dana Farber Cancer Institute, Boston, MA. She has published and lectured on a number of oncology topics, but her specialty is in the field of multiple myeloma, and she works with the myeloma group at Dana Farber Cancer Institute.

Activity type

Patient Management & Therapeutics

Accreditation Statement

logo acpe

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.

This activity has been approved for .1 CEU

This course is also included as part of the Best of AC2017 Bundle product.

Release Date: August 31, 2017

Expiration Date: March 29, 2020

Member: $25

Non-Member: $35

Purchase Now